6-Thioguanine: A naked bullet? (or how pharmacogenomics can make old drugs brand new)

Inflammatory Bowel Diseases

Volumn 7, Issue 3, 2001, Pages 190-191

  Baert, Filip ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DNA; MERCAPTOPURINE; PANCREAS ENZYME; PURINE; STEROID; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ARTHRALGIA; BLOOD CELL COUNT; CROHN DISEASE; DISEASE ASSOCIATION; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FEVER; GENETIC POLYMORPHISM; HUMAN; INHIBITION KINETICS; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; PANCREATITIS; PATIENT MONITORING; PATIENT SELECTION; PHARMACOGENOMICS; PRIORITY JOURNAL; PURINE SYNTHESIS; RASH; REMISSION; ULCERATIVE COLITIS;

EID: 0034888112     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200108000-00002     Document Type: Editorial

References (9)

1. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: Correlation with treatment efficacy
2. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
3. Pharmacogenomics and metabolite measurement for 6 mercaptopurine therapy in inflammatory bowel disease
4. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
5. Serial measurements (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
6. An open label pilot study using thioguanine as a therapeutic alternative to in Crohn's disease patients resistant to 6 mercaptopurine therapy
7. Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
8. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism
9. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematological toxicity: Implications for drug monitoring in children with acute lymphoblastic leukemia